China demands drug suppliers boost imports to combat rise in winter respiratory diseases
- Doctors complain of a drug shortage amid a spike in infectious diseases caused by multiple pathogens
- Azithromycin is among the treatments in short supply after being much sought after and subject to overuse and misuse in China
A report posted on State Council website gov.cn said the rise of seasonal infectious diseases had rapidly pushed up demand for imported drugs, including azithromycin for injection, an antibiotic used to treat a range of infections.
Azithromycin is included on China’s National Reimbursement Drug List (NRDL) which lists government-selected drugs eligible for full or partial reimbursement every year.
02:43
China calls for people to 'minimise personal movement and visits' as respiratory illness cases surge
Although most are domestic medicines, some imported pharmaceuticals such as azithromycin injections are also on the list.
These drugs are bought by the government via designated companies. By buying in bulk, the government can lower the price of the drugs on the NRDL.
During the spikes last year many hospitals were overwhelmed by patients and internet users scrambled for the antibiotics to treat their children despite warnings from doctors that the drug should only be used under prescription.
